HLscience Co. Ltd (239610) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of HLscience Co. Ltd KRW 5,889, price KRW 5,210, upside +13.0%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
HLscience Co., Ltd. manufactures and sells health functional foods in South Korea. The company offers organic barley grassjuice powder one day, queen's pomegranate jin, Super LuzieA+ Astaxanthin, Dr. Superkhan, HL-JOINT 100 for Joint & Cartilage Premium, Dr.
Show more
HLscience Co., Ltd. manufactures and sells health functional foods in South Korea. The company offers organic barley grassjuice powder one day, queen's pomegranate jin, Super LuzieA+ Astaxanthin, Dr. Superkhan, HL-JOINT 100 for Joint & Cartilage Premium, Dr. Green Propolis, morosil diet fit, skin master secret, enerlinger vitamin D, PS300 formulated by doctor, Skin Master P-estro, and Dr. Prebiotics Plus. It also provides CDMO, contract development organization and contract research organization, contract manufacturing organization, quality assurance system, and funding services. Its products are used for antioxidant/skin health/immune function, female menopausal health/skin moisturizing/UV care, liver health, cartilage and joint health/bone health, body fat reduction/energy metabolism, brain health/blood circulation improvement, and gut health applications. The company was founded in 2000 and is headquartered in Hwaseong-si, South Korea.
Stock analysis
HLscience Co. Ltd (239610) currently trades at 5,210 KRW, while our model-based Fair Value estimate is 5,889 KRW, implying the stock looks roughly 11.5% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: 3,887 KRW (bear) to 7,361 KRW (bull), the price of 5,210 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
HLscience Co. Ltd reported revenue of 16.7B KRW in FY2025 versus 104B KRW in FY2021, a compound −36.7%/yr. Reported net income was −11.9B KRW in FY2025.
Key figures
Market cap 26.5B KRW (≈ $19.8M) · P/S ratio 2.54 · Net margin −71.3% · Return on equity −13.4% · Return on assets (EBIT) −3.1% · Operating margin −112% · Revenue (TTM) 10.4B KRW · Revenue growth (YoY) −57.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 53% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 13%, 239610 screens cheaper than that median.
Fair Value models
Bear 3,887 KRWFair Value 5,889 KRWBull 7,361 KRW
Price 5,210 KRW · Upside +13.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.9%
Start year 2020 (pandemic). Over 10 years: −3.4% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.5% (2020) → −66.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 600 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is HLscience Co. Ltd (239610) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 5,889 KRW versus a price of 5,210 KRW, about +13% upside (undervalued).
What is the fair value of 239610?
Our model-based fair value for HLscience Co. Ltd is 5,889 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 5,210 KRW.
What is the quality score of 239610?
HLscience Co. Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HLscience Co. Ltd (239610)?
Our model-based price target is the fair value of 5,889 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 3,887 KRW, optimistic scenario 7,361 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the HLscience Co. Ltd stock forecast for 2026?
Our models put fair value at 5,889 KRW, about +13% upside versus a price of 5,210 KRW (undervalued). Cautious scenario 3,887 KRW, optimistic scenario 7,361 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of HLscience Co. Ltd (239610)?
HLscience Co. Ltd reported trailing-twelve-month revenue of about 10.4B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of HLscience Co. Ltd (239610)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HLscience Co. Ltd it is 5,889 KRW per share (as of Oct 3, 2026), against a price of 5,210 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is HLscience Co. Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 239610 trades below its calculated fair value: price 5,210 KRW, fair value 5,889 KRW, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 239610?
No. The price is what the market pays today (5,210 KRW); the fair value is what the company's own numbers justify (5,889 KRW). For HLscience Co. Ltd the two are 679.11 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is HLscience Co. Ltd worth?
The market values HLscience Co. Ltd at about 26.5B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 5,210 KRW; our models calculate a fair value of 5,889 KRW per share.
What do the bullish and bearish scenarios say about 239610?
Our models span a range for HLscience Co. Ltd: cautious scenario 3,887 KRW, base 5,889 KRW, optimistic 7,361 KRW per share (as of Oct 3, 2026, price 5,210 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of HLscience Co. Ltd (239610)?
Balance-sheet figures for HLscience Co. Ltd (as of Oct 3, 2026): return on equity −13.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 239610 from its 52-week high?
HLscience Co. Ltd trades at 5,210 KRW, about 53% below its 52-week high of 10,980 KRW and 2% above the low of 5,090 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 5,889 KRW is for.
Which stocks are comparable to HLscience Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HLscience Co. Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 5,210 KRW, calculated fair value 5,889 KRW (+13%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 239610 calculated?
We run HLscience Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5,889 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. HLscience Co. Ltd currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HLscience Co. Ltd (239610)?
The closing price on Oct 2, 2026 was 5,210 KRW. Our model-based fair value is 5,889 KRW, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HLscience Co. Ltd right now?
A fairly wide model range (3,887 KRW to 7,361 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of HLscience Co. Ltd
How large is the market capitalisation of HLscience Co. Ltd (239610)?
The market capitalisation of HLscience Co. Ltd is 26.5B KRW (≈ $19.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HLscience Co. Ltd (239610)?
The price-to-sales ratio of HLscience Co. Ltd is 2.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of HLscience Co. Ltd (239610)?
The net margin of HLscience Co. Ltd is −71.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HLscience Co. Ltd (239610)?
The return on equity (ROE) of HLscience Co. Ltd is −13.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HLscience Co. Ltd (239610)?
On an EBIT basis the return on assets of HLscience Co. Ltd is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HLscience Co. Ltd (239610)?
The operating margin of HLscience Co. Ltd is −112% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HLscience Co. Ltd (239610)?
Revenue at HLscience Co. Ltd is growing −57.1% versus a year earlier (3y avg −31.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HLscience Co. Ltd (239610)?
Earnings per share at HLscience Co. Ltd are growing −94.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does HLscience Co. Ltd (239610) generate?
The free cash flow of HLscience Co. Ltd is −7.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch HLscience Co. Ltd in the live analysis
One click puts HLscience Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
